Evidence map›Paper›PMID 41696747›Full record

ArticleFrontiers in neurology2025

Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States.

Cécile Blein, Chafic Karam, Clémence Arvin-Berod, Deborah Gelinas, Sergio Barrera-Sierra, Hashmath Ulla T A Syed, Charlotte Ward, Amit Goyal, Jeffrey Guptill

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cécile Bleinargenx BVBA, Ghent, Belgium.
Chafic KaramDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, United States.
Clémence Arvin-Berodargenx BVBA, Ghent, Belgium.
Deborah Gelinasargenx US, Inc., Boston, MA, United States.
Sergio Barrera-Sierraargenx BVBA, Ghent, Belgium.
Hashmath Ulla T A SyedZS Associates, Bengaluru, India.
Charlotte WardZS Associates, Bethesda, MD, United States.
Amit GoyalZS Associates, Princeton, NJ, United States.
Jeffrey Guptillargenx US, Inc., Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Management of chronic inflammatory demyelinating polyneuropathy (CIDP) is challenged by heterogeneity in severity, comorbidities, potential adverse effects, and treatment accessibility. This study aimed to elucidate treatment utilization among patients with CIDP in the United States (US) to identify potential unmet needs. Methods: Adult patients with CIDP were identified using Komodo Health's Healthcare Map™ (January 2016-December 2020). Descriptive statistics related to utilization of CIDP treatments over 1-year post-index were analyzed. Among patients who used immunoglobulin (Ig), chronic Ig users were defined as patients with ≥8 Ig courses, and intermittent Ig users as patients with <8 Ig courses during 1-year post-index. Results: Among 3,409 patients with CIDP identified, the majority (81% [ Conclusion: Steroids and Ig were mainstay treatments among patients with CIDP. A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.

Indexed as

chronic inflammatory demyelinating polyradiculoneuropathyclaims databaseimmunoglobulinreal-world evidencetreatment utilization

Identifiers

PMID41696747
PMCPMC12896209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.